SOPHiA Genetics SA (NASDAQ:SOPH – Get Rating)’s share price was up 4.4% during trading on Friday . The stock traded as high as $10.65 and last traded at $10.65. Approximately 130 shares were traded during trading, a decline of 100% from the average daily volume of 90,020 shares. The stock had previously closed at $10.20.
Several equities analysts have commented on SOPH shares. Morgan Stanley lowered their target price on shares of SOPHiA Genetics from $23.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 15th. Zacks Investment Research downgraded shares of SOPHiA Genetics from a “hold” rating to a “sell” rating in a research report on Friday, February 18th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $21.00.
The company’s 50-day simple moving average is $12.17 and its 200 day simple moving average is $14.44.
Hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp bought a new stake in SOPHiA Genetics during the fourth quarter valued at about $89,000. Compagnie Lombard Odier SCmA bought a new stake in SOPHiA Genetics during the third quarter valued at about $140,000. UBS Group AG bought a new stake in SOPHiA Genetics during the third quarter valued at about $187,000. Geode Capital Management LLC bought a new stake in SOPHiA Genetics during the fourth quarter valued at about $189,000. Finally, Citadel Advisors LLC bought a new stake in SOPHiA Genetics during the fourth quarter valued at about $200,000. Institutional investors own 29.08% of the company’s stock.
About SOPHiA Genetics (NASDAQ:SOPH)
SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.
Read More
- Get a free copy of the StockNews.com research report on SOPHiA Genetics (SOPH)
- Can Gaming Be the Catalyst That Drives HOFV Stock Higher?
- 4 Best Sporting Goods Stocks that Hit it Out of the Park
- 3 Intriguing International Stocks to Buy Now
- MarketBeat: Week in Review 3/7 – 3/11
- Is Netflix (NASDAQ: NFLX) About To Rise From The Ashes?
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 “MUST OWN” Growth Stocks
Receive News & Ratings for SOPHiA Genetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SOPHiA Genetics and related companies with MarketBeat.com’s FREE daily email newsletter.